Real-World Outcomes of Anti-VEGF Treatment for Retinal Vein Occlusion in Portugal

Purpose Retinal vein occlusion (RVO) is an important cause of visual disability in the modern world. We aim to evaluate the real-world outcomes of patients with RVO treated with anti-vascular endothelial growth factor (VEGF) in Portugal. Methods We performed a retrospective, observational, multicent...

Full description

Saved in:
Bibliographic Details
Published in:European journal of ophthalmology 2017-11, Vol.27 (6), p.756-761
Main Authors: Vaz-Pereira, Sara, Marques, Inês P., Matias, João, Mira, Filipe, Ribeiro, Lígia, Flores, Rita
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c387t-997a1ca59fc04f095863cfdf00ab5cbbf18105908233b23dd1feb4fb7959543e3
cites cdi_FETCH-LOGICAL-c387t-997a1ca59fc04f095863cfdf00ab5cbbf18105908233b23dd1feb4fb7959543e3
container_end_page 761
container_issue 6
container_start_page 756
container_title European journal of ophthalmology
container_volume 27
creator Vaz-Pereira, Sara
Marques, Inês P.
Matias, João
Mira, Filipe
Ribeiro, Lígia
Flores, Rita
description Purpose Retinal vein occlusion (RVO) is an important cause of visual disability in the modern world. We aim to evaluate the real-world outcomes of patients with RVO treated with anti-vascular endothelial growth factor (VEGF) in Portugal. Methods We performed a retrospective, observational, multicenter study including 8 centers across Portugal and 200 patients treated with either ranibizumab or bevacizumab. Data were collected at 3 time points: time of diagnosis (0 time point) and 6 and 12 months after initiating treatment. Demographic and clinical data were collected. Results Median visual acuity (VA) and central macular thickness (CMT) improved in the branch RVO (BRVO), central RVO (CRVO), bevacizumab, and ranibizumab groups at 6 and 12 months compared to baseline, with CMT improving further only in the CRVO and ranibizumab groups between 6 and 12 months (p = 0.002 and p = 0.001, respectively). The CMT was lower in the ranibizumab group compared to the bevacizumab group both at 6 and 12 months (p
doi_str_mv 10.5301/ejo.5000943
format article
fullrecord <record><control><sourceid>sage_cross</sourceid><recordid>TN_cdi_crossref_primary_10_5301_ejo_5000943</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.5301_ejo.5000943</sage_id><sourcerecordid>10.5301_ejo.5000943</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-997a1ca59fc04f095863cfdf00ab5cbbf18105908233b23dd1feb4fb7959543e3</originalsourceid><addsrcrecordid>eNptkEFLwzAYhoMoOKcn_0COgmR-SZq2OY6xTWFQHXMeS5omo6VtJEkP_nsr29HT937w8ML7IPRIYSE40BfTuoUAAJnwKzSjGUtICjS9njJlQNKM0Vt0F0ILwCaIzdDH3qiOfDnf1bgYo3a9CdhZvBxiQ47r7QYfvFGxN0PE1nm8N7EZVIePphlwoXU3hsYNeHrenY_jSXX36MaqLpiHy52jz836sHolu2L7tlruiOZ5FomUmaJaCWk1JBakyFOubW0BVCV0VVmaUxAScsZ5xXhdU2uqxFaZFFIk3PA5ej73au9C8MaW377plf8pKZR_NsrJRnmxMdFPZzqokylbN_ppRfgX_QUG7l8G</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Real-World Outcomes of Anti-VEGF Treatment for Retinal Vein Occlusion in Portugal</title><source>SAGE:Jisc Collections:SAGE Journals Read and Publish 2023-2024:2025 extension (reading list)</source><creator>Vaz-Pereira, Sara ; Marques, Inês P. ; Matias, João ; Mira, Filipe ; Ribeiro, Lígia ; Flores, Rita</creator><creatorcontrib>Vaz-Pereira, Sara ; Marques, Inês P. ; Matias, João ; Mira, Filipe ; Ribeiro, Lígia ; Flores, Rita</creatorcontrib><description>Purpose Retinal vein occlusion (RVO) is an important cause of visual disability in the modern world. We aim to evaluate the real-world outcomes of patients with RVO treated with anti-vascular endothelial growth factor (VEGF) in Portugal. Methods We performed a retrospective, observational, multicenter study including 8 centers across Portugal and 200 patients treated with either ranibizumab or bevacizumab. Data were collected at 3 time points: time of diagnosis (0 time point) and 6 and 12 months after initiating treatment. Demographic and clinical data were collected. Results Median visual acuity (VA) and central macular thickness (CMT) improved in the branch RVO (BRVO), central RVO (CRVO), bevacizumab, and ranibizumab groups at 6 and 12 months compared to baseline, with CMT improving further only in the CRVO and ranibizumab groups between 6 and 12 months (p = 0.002 and p = 0.001, respectively). The CMT was lower in the ranibizumab group compared to the bevacizumab group both at 6 and 12 months (p&lt;0.02). Median CMT improved in both the good and poor baseline VA groups at 6 and 12 months compared to baseline (p&lt;0.001). Median VA only improved for the group with poor baseline VA at 6 and 12 months of follow-up (p&lt;0.001). Regression analysis identified several baseline variables as predictors of visual outcomes at 6 and 12 months, with different results depending on the analyzed group. Conclusions Both treatments were effective, although less effective than results reported in clinical trials. The morphologic response was better with ranibizumab compared to bevacizumab, although functionally there were no differences.</description><identifier>ISSN: 1120-6721</identifier><identifier>EISSN: 1724-6016</identifier><identifier>DOI: 10.5301/ejo.5000943</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><ispartof>European journal of ophthalmology, 2017-11, Vol.27 (6), p.756-761</ispartof><rights>2017 SAGE Publications</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-997a1ca59fc04f095863cfdf00ab5cbbf18105908233b23dd1feb4fb7959543e3</citedby><cites>FETCH-LOGICAL-c387t-997a1ca59fc04f095863cfdf00ab5cbbf18105908233b23dd1feb4fb7959543e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Vaz-Pereira, Sara</creatorcontrib><creatorcontrib>Marques, Inês P.</creatorcontrib><creatorcontrib>Matias, João</creatorcontrib><creatorcontrib>Mira, Filipe</creatorcontrib><creatorcontrib>Ribeiro, Lígia</creatorcontrib><creatorcontrib>Flores, Rita</creatorcontrib><title>Real-World Outcomes of Anti-VEGF Treatment for Retinal Vein Occlusion in Portugal</title><title>European journal of ophthalmology</title><description>Purpose Retinal vein occlusion (RVO) is an important cause of visual disability in the modern world. We aim to evaluate the real-world outcomes of patients with RVO treated with anti-vascular endothelial growth factor (VEGF) in Portugal. Methods We performed a retrospective, observational, multicenter study including 8 centers across Portugal and 200 patients treated with either ranibizumab or bevacizumab. Data were collected at 3 time points: time of diagnosis (0 time point) and 6 and 12 months after initiating treatment. Demographic and clinical data were collected. Results Median visual acuity (VA) and central macular thickness (CMT) improved in the branch RVO (BRVO), central RVO (CRVO), bevacizumab, and ranibizumab groups at 6 and 12 months compared to baseline, with CMT improving further only in the CRVO and ranibizumab groups between 6 and 12 months (p = 0.002 and p = 0.001, respectively). The CMT was lower in the ranibizumab group compared to the bevacizumab group both at 6 and 12 months (p&lt;0.02). Median CMT improved in both the good and poor baseline VA groups at 6 and 12 months compared to baseline (p&lt;0.001). Median VA only improved for the group with poor baseline VA at 6 and 12 months of follow-up (p&lt;0.001). Regression analysis identified several baseline variables as predictors of visual outcomes at 6 and 12 months, with different results depending on the analyzed group. Conclusions Both treatments were effective, although less effective than results reported in clinical trials. The morphologic response was better with ranibizumab compared to bevacizumab, although functionally there were no differences.</description><issn>1120-6721</issn><issn>1724-6016</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNptkEFLwzAYhoMoOKcn_0COgmR-SZq2OY6xTWFQHXMeS5omo6VtJEkP_nsr29HT937w8ML7IPRIYSE40BfTuoUAAJnwKzSjGUtICjS9njJlQNKM0Vt0F0ILwCaIzdDH3qiOfDnf1bgYo3a9CdhZvBxiQ47r7QYfvFGxN0PE1nm8N7EZVIePphlwoXU3hsYNeHrenY_jSXX36MaqLpiHy52jz836sHolu2L7tlruiOZ5FomUmaJaCWk1JBakyFOubW0BVCV0VVmaUxAScsZ5xXhdU2uqxFaZFFIk3PA5ej73au9C8MaW377plf8pKZR_NsrJRnmxMdFPZzqokylbN_ppRfgX_QUG7l8G</recordid><startdate>20171108</startdate><enddate>20171108</enddate><creator>Vaz-Pereira, Sara</creator><creator>Marques, Inês P.</creator><creator>Matias, João</creator><creator>Mira, Filipe</creator><creator>Ribeiro, Lígia</creator><creator>Flores, Rita</creator><general>SAGE Publications</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20171108</creationdate><title>Real-World Outcomes of Anti-VEGF Treatment for Retinal Vein Occlusion in Portugal</title><author>Vaz-Pereira, Sara ; Marques, Inês P. ; Matias, João ; Mira, Filipe ; Ribeiro, Lígia ; Flores, Rita</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-997a1ca59fc04f095863cfdf00ab5cbbf18105908233b23dd1feb4fb7959543e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vaz-Pereira, Sara</creatorcontrib><creatorcontrib>Marques, Inês P.</creatorcontrib><creatorcontrib>Matias, João</creatorcontrib><creatorcontrib>Mira, Filipe</creatorcontrib><creatorcontrib>Ribeiro, Lígia</creatorcontrib><creatorcontrib>Flores, Rita</creatorcontrib><collection>CrossRef</collection><jtitle>European journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vaz-Pereira, Sara</au><au>Marques, Inês P.</au><au>Matias, João</au><au>Mira, Filipe</au><au>Ribeiro, Lígia</au><au>Flores, Rita</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real-World Outcomes of Anti-VEGF Treatment for Retinal Vein Occlusion in Portugal</atitle><jtitle>European journal of ophthalmology</jtitle><date>2017-11-08</date><risdate>2017</risdate><volume>27</volume><issue>6</issue><spage>756</spage><epage>761</epage><pages>756-761</pages><issn>1120-6721</issn><eissn>1724-6016</eissn><abstract>Purpose Retinal vein occlusion (RVO) is an important cause of visual disability in the modern world. We aim to evaluate the real-world outcomes of patients with RVO treated with anti-vascular endothelial growth factor (VEGF) in Portugal. Methods We performed a retrospective, observational, multicenter study including 8 centers across Portugal and 200 patients treated with either ranibizumab or bevacizumab. Data were collected at 3 time points: time of diagnosis (0 time point) and 6 and 12 months after initiating treatment. Demographic and clinical data were collected. Results Median visual acuity (VA) and central macular thickness (CMT) improved in the branch RVO (BRVO), central RVO (CRVO), bevacizumab, and ranibizumab groups at 6 and 12 months compared to baseline, with CMT improving further only in the CRVO and ranibizumab groups between 6 and 12 months (p = 0.002 and p = 0.001, respectively). The CMT was lower in the ranibizumab group compared to the bevacizumab group both at 6 and 12 months (p&lt;0.02). Median CMT improved in both the good and poor baseline VA groups at 6 and 12 months compared to baseline (p&lt;0.001). Median VA only improved for the group with poor baseline VA at 6 and 12 months of follow-up (p&lt;0.001). Regression analysis identified several baseline variables as predictors of visual outcomes at 6 and 12 months, with different results depending on the analyzed group. Conclusions Both treatments were effective, although less effective than results reported in clinical trials. The morphologic response was better with ranibizumab compared to bevacizumab, although functionally there were no differences.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><doi>10.5301/ejo.5000943</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1120-6721
ispartof European journal of ophthalmology, 2017-11, Vol.27 (6), p.756-761
issn 1120-6721
1724-6016
language eng
recordid cdi_crossref_primary_10_5301_ejo_5000943
source SAGE:Jisc Collections:SAGE Journals Read and Publish 2023-2024:2025 extension (reading list)
title Real-World Outcomes of Anti-VEGF Treatment for Retinal Vein Occlusion in Portugal
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T04%3A29%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-sage_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real-World%20Outcomes%20of%20Anti-VEGF%20Treatment%20for%20Retinal%20Vein%20Occlusion%20in%20Portugal&rft.jtitle=European%20journal%20of%20ophthalmology&rft.au=Vaz-Pereira,%20Sara&rft.date=2017-11-08&rft.volume=27&rft.issue=6&rft.spage=756&rft.epage=761&rft.pages=756-761&rft.issn=1120-6721&rft.eissn=1724-6016&rft_id=info:doi/10.5301/ejo.5000943&rft_dat=%3Csage_cross%3E10.5301_ejo.5000943%3C/sage_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c387t-997a1ca59fc04f095863cfdf00ab5cbbf18105908233b23dd1feb4fb7959543e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_sage_id=10.5301_ejo.5000943&rfr_iscdi=true